Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Alternative Donor Transplantation Using Intensified Conditioning, T-Cell-Replete HLA-Haploidentical Grafts and Post-Transplantation Cyclophosphamide in the Treatment of High-Risk and Advanced ALL: Feasibility and Outcome

Blood (2016) 128 (22): 2224.

https://doi.org/10.1182/blood.V128.22.2224.2224

Published: 2016

Journal Articles

Feasibility and Outcome of Sequential Therapy in the Setting of HLA-Haploidentical Transplantation Utilizing Reduced-Intensity Conditioning, T-Cell-Replete Grafts and Post-Transplantation High-Dose Cyclophosphamide in the Treatment of High-Risk AML and MDS

Dusan Prevalsek, MD, Susanne Fritsch, MD, Max Hubmann, MD, Nicole Engel, MD, Anna-Katharina Zoellner, MD, Thomas Köhnke, MD, Veit Leonhard Bücklein, MD, Christoph Schulz, MD, Friederike Mumm, MD, Christina Theresa Rieger, MD, Georg Ledderose, MD, Hans-Joachim Stemmler, MD, Karsten Spiekermann, MD, Wolfgang Hiddemann, MD, Andreas Hausmann, MD, Johanna Tischer, MD

Blood (2015) 126 (23): 4318.

https://doi.org/10.1182/blood.V126.23.4318.4318

Published: 2015

Journal Articles

Allogeneic Transplantation in Elderly Patients with AML and MDS Comparing Reduced-Intensity Conditioning with Flamsa-Busulfan Versus Fludarabine/BCNU/Melphalan

Nicole Engel, MD, Wolfgang Hill, MD, Susanne Fritsch, MD, Dusan Prevalsek, MD, Anna-Katharina Zoellner, MD, Max Hubmann, MD, Veit Buecklein, MD, Andreas Hausmann, MD, Georg Ledderose, MD, Hans-Jochem Kolb, PhD, Wolfgang Hiddemann, MD, Johanna Tischer, MD

Blood (2014) 124 (21): 5839.

https://doi.org/10.1182/blood.V124.21.5839.5839

Published: 2014

Journal Articles

Sequential Therapy Combining Clofarabine and HLA-Haploidentical Hematopoietic Stem Cell Transplantation In The Treatment Of Refractory and Advanced Lymphoma: Feasibility, Toxicity and Early Outcome

Anna-Katharina Zoellner, Susanne Fritsch, MD, Dusan Prevalsek, MD, Nicole Engel, MD, Roland Reibke, MD, Christina T Rieger, MD, PhD, Georg Ledderose, MD, Wolfgang Hiddemann, MD, Martin Dreyling, Andreas Hausmann, MD, Johanna Tischer, MD

Blood (2013) 122 (21): 4544.

https://doi.org/10.1182/blood.V122.21.4544.4544

Published: 2013

Journal Articles

Clofarabine Cytoreduction Followed by a Second Transplant Using Haploidentical Donors for Relapsed Acute Leukemia After First Allogeneic Hematopoietic Stem Cell Transplantation: Early Outcome, Infection and Toxicity.

Johanna Tischer, MD, Susanne Fritsch, MD, Dusan Prevalsek, MD, Max Hubmann, MD, Veit Bücklein, Anna K Zöllner, MD, Christoph Schulz, MD, Roland Reibke, MD, Nicole Engel, MD, Christina T Rieger, MD, PhD, Christoph Schmid, MD, PhD, Georg Ledderose, MD, Wolfgang Hiddemann, MD, PhD, Andreas Hausmann, MD

Blood (2012) 120 (21): 3071.

https://doi.org/10.1182/blood.V120.21.3071.3071

Published: 2012

Journal Articles

Long-Term Results of Donor Lymphocyte Transfusions for the Treatment of Relapse After Allogeneic Transplantation for Chronic Myelogenous Leukemia - Is There a Role for Immunotherapy in CML?.

Hans-Jochem Kolb, Dagmar Bund, PhD, Helga Schmetzer, PhD, Prof, Christoph Schmid, MD, PhD, Raymund Buhmann, MD, Johanna Tischer, MD, Georg Ledderose, MD

Blood (2009) 114 (22): 2258.

https://doi.org/10.1182/blood.V114.22.2258.2258

Published: 2009

Journal Articles

Bone Marrow Reaction in Patients with Chronic GvHD - An Immunohistochemical Analysis of Microvessels and Lymphocytes.

Wolfgang Hill, MD, Ralf Huss, MD, Johanna Ullmann, Georg Ledderose, MD, Johanna Tischer, MD, Andreas Hausmann, MD, Hans-Jochem Kolb, MD

Blood (2007) 110 (11): 1963.

https://doi.org/10.1182/blood.V110.11.1963.1963

Published: 2007

Journal Articles

Treatment of Relapse of AML and MDS after Allogeneic Stem Cell Transplantation Using Low-Dose Chemotherapy, Donor PBSC and GM-CSF: Final Results from a Prospective, Multicenter Phase II Trial by the German Cooperative Transplant Group.

Christoph Schmid, MD, Johanna Tischer, MD, Matthias Stelljes, MD, Michael Schleuning, MD, Rainer Schwerdtfeger, MD, Ute Hegenbart, MD, Joerg Schubert, MD, Wichard Vogel, MD, Berd Gruhn, MD, Christiane Lallinger, Georg Ledderose, MD, Martin Bornhaeuser, MD, Joachim Kienast, MD, Hans-Jochem Kolb, MD

Blood (2007) 110 (11): 1651.

https://doi.org/10.1182/blood.V110.11.1651.1651

Published: 2007

Journal Articles

Allogeneic Stem Cell Transplantation for MDS and sAML Following Reduced Intensity Conditioning and Preemptive Donor Lymphocyte Transfusion.

Hans-Jochem Kolb, MD, PhD, Christoph Schmid, MD, Johanna Tischer, MD, Andreas Haussmann, MD, Andreas Rank, MD, Michael Schleuning, MD, Georg Ledderose, MD

Blood (2006) 108 (11): 324.

https://doi.org/10.1182/blood.V108.11.324.324

Published: 2006

Journal Articles

Treatment of Osteopenia/Osteoporosis after Allogeneic Hematological Cell Transplantation with Zoledronic Acid.

Wolfgang Hill, MD, Johanna Ullmann, Andrea Baur, MD, Georg Ledderose, MD, Johanna Tischer, MD, Dieter Muehlbayer, MD, Andreas Hausmann, MD, Michael Schmidt, Ulrike Haus, Hans-Jochem Kolb, MD

Blood (2006) 108 (11): 3368.

https://doi.org/10.1182/blood.V108.11.3368.3368

Published: 2006

Journal Articles

Risk Factors of HLA-Haploidentical Transplantation Using the Combination of Unmodified Marrow and CD6-Depleted G-CSF Mobilized Blood Cells.

Hans-Jochem Kolb, MD, PhD, Iris Bigalke, MD, Johanna Tischer, MD, Wolfgang Hill, MD, Christine Falk, PhD, Belinda Simoes, MD, Christoph Schmid, MD, Georg Ledderose, MD

Blood (2005) 106 (11): 2907.

https://doi.org/10.1182/blood.V106.11.2907.2907

Published: 2005

Journal Articles

CD6-Depleted Mobilized Stem Cells for Modification of HVG and GVH Reactions after HLA-Haploidentical Marrow Transplantation.

Hans-Jochem Kolb, MD, Iris Bigalke, MD, Belinda Simoes, MD, Christine Falk, PhD, Johanna Tischer, MD, Wolfgang Hill, MD, Georg Ledderose, MD

Blood (2004) 104 (11): 978.

https://doi.org/10.1182/blood.V104.11.978.978

Published: 2004

Journal Articles

A Comparison of Acute GVHD after HLA-Haploidentical and HLA-Identical Stem Cell Transplantation.

Wolfgang Hill, MD, Johanna Tischer, MD, Iris Bigalke, MD, Christina Rieger, MD, Georg Ledderose, MD, Hans-Jochem Kolb, MD

Blood (2004) 104 (11): 2151.

https://doi.org/10.1182/blood.V104.11.2151.2151

Published: 2004

NARROW

Alternative Donor Transplantation Using Intensified Conditioning, T-Cell-Replete HLA-Haploidentical Grafts and Post-Transplantation Cyclophosphamide in the Treatment of High-Risk and Advanced ALL: Feasibility and Outcome

Feasibility and Outcome of Sequential Therapy in the Setting of HLA-Haploidentical Transplantation Utilizing Reduced-Intensity Conditioning, T-Cell-Replete Grafts and Post-Transplantation High-Dose Cyclophosphamide in the Treatment of High-Risk AML and MDS

Allogeneic Transplantation in Elderly Patients with AML and MDS Comparing Reduced-Intensity Conditioning with Flamsa-Busulfan Versus Fludarabine/BCNU/Melphalan

Sequential Therapy Combining Clofarabine and HLA-Haploidentical Hematopoietic Stem Cell Transplantation In The Treatment Of Refractory and Advanced Lymphoma: Feasibility, Toxicity and Early Outcome

Clofarabine Cytoreduction Followed by a Second Transplant Using Haploidentical Donors for Relapsed Acute Leukemia After First Allogeneic Hematopoietic Stem Cell Transplantation: Early Outcome, Infection and Toxicity.

Long-Term Results of Donor Lymphocyte Transfusions for the Treatment of Relapse After Allogeneic Transplantation for Chronic Myelogenous Leukemia - Is There a Role for Immunotherapy in CML?.

Bone Marrow Reaction in Patients with Chronic GvHD - An Immunohistochemical Analysis of Microvessels and Lymphocytes.

Treatment of Relapse of AML and MDS after Allogeneic Stem Cell Transplantation Using Low-Dose Chemotherapy, Donor PBSC and GM-CSF: Final Results from a Prospective, Multicenter Phase II Trial by the German Cooperative Transplant Group.

Allogeneic Stem Cell Transplantation for MDS and sAML Following Reduced Intensity Conditioning and Preemptive Donor Lymphocyte Transfusion.

Treatment of Osteopenia/Osteoporosis after Allogeneic Hematological Cell Transplantation with Zoledronic Acid.

Risk Factors of HLA-Haploidentical Transplantation Using the Combination of Unmodified Marrow and CD6-Depleted G-CSF Mobilized Blood Cells.

CD6-Depleted Mobilized Stem Cells for Modification of HVG and GVH Reactions after HLA-Haploidentical Marrow Transplantation.

A Comparison of Acute GVHD after HLA-Haploidentical and HLA-Identical Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only